Tag: featured

안녕하세요.

다가오는 11월 17과 18일에 개최되는 한미 생명과학인 협회(카팔) 연례 컨퍼런스 (KAPAL Annual Conference, KAC)* 와 18일에 있을 ABES에 여러분을 초대합니다.

REGISTRATION for the 6th KAPAL Annual Conference

카팔 연례학회는 신약 연구•개발 및 상용화 관련 전문가들이 모여 신약연구 및 개발, 물질특허 및 미국 내 임상 시험에 대한 사례등의 의견을 서로 교환하고 소통하기 위한 컨퍼런스 입니다. 더불어 한국과 미국 상호간의 의 바이오 사업 추진 및 인재 채용에 적극적으로 동참하여, 양국의 바이어 산업의 무궁한 발전에 기여하기 위해 노력하고 있습니다.

카팔은 미국 정부 기관인 NIH와 FDA뿐 아니라 다수의 규모가 큰 바이오 회사가 위치한 메릴랜드의 지리적인 이점으로, 다양하게 다루어지는 바이오•신약개발 산업 관련 연구자들이 많이 참여하여 활발하게 정보 교환 및 네트워킹이 이루어지고 있습니다.

특별히 제 6 회 카팔연례학회는 아래의 주제들을 중점으로 프로그램을 준비하였습니다.

• 미국내 임상/인허가: 희귀질환 전략, 세포치료제 개발, real world data
• 바이오 투자: 미국 현지의 트렌드와 전략
• 글로벌 제약사의신약 개발 : 미국 현지에서의 신약 개발, 전략, 관련 기업의 전문가들과 네트워킹
• Grant for US Business

카팔연례학회는 한미 양국의 기관 및 기업의 지원을 받아, 메릴랜드 락빌에 위치한 한미 생명과학인협회 (Korean-American Professionals in Life Sciences, KAPAL) 주최로 매년 개최되고 있습니다. 자세한 내용은 행사 웹사이트(www.kapal.org)를 참조해 주시고, 질문과 건의사항은 contact@kapal.org로 문의바랍니다.

*KAPAL 멤버가 되시면 KAC 등록시 등록비 할인을 받으실 수 있습니다.

KAPAL MEMBERSHIP REGISTRATION LINK

**KAC 현장에서 KSEA (Korean-American Scientists and Engineers Association, https://ksea.org/) 회원가입을 무료로 지원 할 예정입니다.

*** 등록 후 현장 참석자에 한해서 한국인삼공사에서 후원하는 소정의 기념품을 증정할 예정입니다.

제 12회 Annual Bioscience & Engineering Symposium (ABES)

11월 18일에 개최되는 ABES는 NIH-KSA (Korean Scientist Association) 에서 준비하는 심포지엄으로, NIH에서 연구하시는 한인 과학자분들의 원천기술과 연구를 발표하는 심포지엄입니다.

2022년에 이룬 다양한 생명과학분야의 연구업적등을 발표함으로써 앞으로의 혁신 신약개발의 발판이 되는 심포지엄이니 많은 관심과 참여 바랍니다. ABES 관련한 자세한 정보는 https://nihksa.org 를 참고 부탁드립니다.

*********************************

The 6th KAPAL Annual Conference (11/17 – 18) & the 12th ABES (11/18)

You are cordially invited to the 6th KAPAL Annual Conference and the 12th ABES. Over the past four years, the conference has grown steadily, with an increasing number of participants from Korea and U.S. Last year, over 250 attendees and over 50 companies came together from multiple disciplines in the life sciences: the healthcare industry, academia, and public research institutions, such as FDA and NIH.

The KAPAL Annual Conference aims to provide business opportunities through collaboration among professionals and companies in drug development and life science. We strive to facilitate the exchange of innovative ideas and strategies for success across the healthcare industry. This year’s conference will be more informative and synergistic for the growth of US-Korea collaboration in pharmaceuticals and biotechnology.

The 6th KAPAL Annual Conference will provide opportunities to:

• Special FDA sessions
• Collaborate with Korean pharmaceutical and biotech companies
• Expand your professional network in the Korean-American life science community
• Develop unique perspectives on the Korean healthcare industry through keynote speakers and other presentations from leading Korean biopharmaceuticals and biotechs

You can find more information and updates at www.kapal.org. Please direct any inquiries and feedback to contact@kapal.org.

*When you become a KAPAL member, you can get a discount for KAC registration.

KAPAL MEMBERSHIP REGISTRATION LINK

*** Only on-site attendees will be given a small souvenir sponsored by the KOREAN RED GINSENG CORP Inc.

The 12th Annual Bioscience & Engineering Symposium (ABES)

NIH-Korean Scientist Association (NIH-KSA) is organizing the 12th ABES on November 18th. The ABES focuses on fundamental research and early discovery in life science. Many exciting findings and reports are to be presented, which may become a platform for new drug development. There will be career development presentations as well to share experiences and tips for all who are interested in the next opportunity. For more information, refer to https://nihksa.org/

We look forward to meeting you at the 6th KAPAL Annual Conference and the 12th ABES

The KAPAL and NIH-KSA committee

2022 KAPAL–KHIDI Bio & Health Webinar Series는 한미생명과학인 협회 (KAPAL)와 KHIDI 미국지사 웨비나 시리즈입니다.

Topic Title: Advantages & strategies for breaking into the West Coast-based U.S market | Sacramento & Los Angeles

KAPAL-CA is hosting a special seminar for Korean biotech & life sciences companies looking to enter the West Coast-based U.S market. As many people are aware, San Francisco and San Diego comprise the largest biotech clusters in the West Coast region. To bring forth different perspectives and introduce nascent and promising regions within California, KAPAL-CA has invited two qualified speakers who can articulate the benefits of Sacramento & Los Angeles as alternative options for Korean companies’ U.S. base of operations.

Invited Speakers:
Troels Adrian | VP of Business Development, Greater Sacramento Economic Council
Dave Whelan | CEO, BioscienceLA

안녕하세요,

이번에 KAPAL 과 KASBP Washington DC Chapter 가 함께 준비한 Joint Networking Dinner 에 여러분을 초대합니다. 코로나 바이러스 팬데믹 동안 못보신 분들과 서로의 안부도 묻고 맛있는 저녁도 함께 드시면서 좋은 말씀 나누시는 기회가 되시기를 진심으로 바랍니다. 석식준비를 위해 등록을 부탁드립니다. 이미 등록을 하셨으면 감사드리고 당일에 꼭 참석해주시기를 부탁드립니다. 혹시 부득이한 사정으로 등록하셨는데 데 참석을 못하실 경우 꼭 등록 취소는 contact@kapal.org 로 간단히 이멜 부탁드립니다.

— 참석수용인원상 가족동반은 아님을 양해바랍니다.

When: Thursday, July 21, 2022, 6 pm – 9 pm

Where: Rollins Congressional Clubhouse1621 Martha TerraceRockville, MD 20852

Hello, you are cordially invited to the 2022 KAPAL-KASBP Washington DC Chapter Joint Networking Dinner, which will be held on July 21, 2022 at 6 pm. There will be Korean catering dinner and drinks ready for you and your colleagues. If you have any questions related to the registration or event, please email to contact@kapal.org (KAPAL) or calciumhwang@gmail.com (KASBP DC Chapter). Please share this invitation with your colleagues and come to join the 2022 KAPAL-KASBP Washington DC Chapter Joint Networking Dinner.

— Private professional adult-only event. — Event will be held in Korean/English

Program Agenda

본 행사는 주 미국 대한민국 대사관에서 주최하며 한국보건산업진흥원 및 한미생명과학인협회 (캘리포니아)에서 주관하는 온라인 웨비나 및 오프라인으로 동시 진행되는 행사 입니다.

이벤트 신청 페이지: https://www.eventbrite.com/e/349092704677

연사 소개

발표 I : 박성원 변호사 (Sung Park) / Reed Smith LLP

Sung provides counsel to FDA-regulated companies in developing, distributing, and marketing FDA-regulated digital health products and, when necessary, in responding to regulatory and administrative enforcement actions by federal and state agencies. Sung frequently counsels clients on FDA’s legal and regulatory requirements and policies for digital health products, and provides counsel that allows companies to comply with FDA’s policies and requirements. Sung has experience in responding to FDA’s various enforcement actions such as warning letters, untitled letters, and form 483 notice of inspectional observations. Sung understands the unique business landscape of FDA-regulated products, and provides practical advice that suits the needs of the client’s business.

발표 II : 윤학희 CEO (Harry Yun) / InBody USA

Harry Yun is the CEO of InBody USA, a prominent medical device company from Korea and a worldwide leader in body composition technology with a mission to provide biomedical technology that simplifies the understanding of health and wellness. InBody USA was established in the year 2000 in Beverly Hills, California and has moved its corporate office to Cerritos, California in 2012. Under Yun’s leadership, InBody continues to successfully penetrate the US market with state-of-the-art technology. Yun is a graduate from Hankuk University of Foreign Studies (HUFS) with Masters in Economics and has extensive experience of International Marketing.

발표 III : 조성환 CTO (Sunghwan Cho) / NanoCellect Biomedical Inc

Sunghwan Cho is the CTO of NanoCellect Biomedical Inc, whose mission is to facilitate breakthrough biomedical discoveries by making cell analysis and sorting technology more affordable and easier to use. He has 15+ years of expertise in integrating microfluidics, optics, micro/nano-fabrication, and electronics for advanced biomedical devices and instruments. He is also an inventor of the company’s core technologies, including its microfluidics-based cell sorting platform, and manages the company’s research project and product development. He was selected as a Marylou Ingram Scholar of the International Society for Advancement of Cytometry (ISAC) from 2012 to 2017, recognized for his contribution to the field of cytometry.

2022 KAPAL–KHIDI Bio & Health Webinar Series는 한미생명과학인 협회 (KAPAL)와 KHIDI 미국지사 웨비나 시리즈입니다.

Topic Title: US R&D Tax Credit & Corporate Tax

o “US R&D Tax Credit Introduction”

Christina Ahn, CPA, R&D Credit Specialist, Ardius (acquired by Gusto)

o “US Corporate Tax Filing Requirements and Transfer Pricing Issues”

Alex Koo, Tax Partner, KPMG LLP / Shawn Kim, Managing Director, KPMG LLP

About the presenter:

Christina Ahn, CPA

R&D Credit Specialist, Ardius (acquired by Gusto)

Co-founder and CEO, Pinecone41

Pinecone41 is a Fintech startup that specializes in R&D Tax Credit services and provide technology startups accurate and beneficial tax insights that can be used to fuel growth.

Top Skills

Financial Analysis, Data Analysis, Corporate Tax

Experience

Ardius (acquired by Gusto, R&D Credit Specialist), Pinecone41 (CEO), KPMG (Tax Manager), Deloitte Tax LLP (Senior Tax Consultant), Mah & Associates (Staff Accountant)

Alex Koo

Tax Partner, KPMG LLP

Alex is a Tax Partner in KPMG’s Los Angeles Federal Tax Services, Korean practice. Before joining KPMG, Alex started his career in the tax department of Deloitte Korea and performed various tax projects until he was seconded to the US office. He has more than 20 years of experience in U.S. and Korea tax consulting, income tax compliance and income tax provision.

Alex is responsible for a broad range of U.S. multi-national and foreign-owned clients doing business as single entities or joint ventures, and has extensive experience with a wide range of tax matters relating to multi-national businesses. Alex’s current and past clients include leaders in the industrial production industries and high-technology, media, and telecommunication industries.

Alex has provided tax compliance services for various engagements in size from private to multi-national public companies in the U.S. and Korea and has extensive experience in defending corporations against tax examinations by Federal and state tax authorities.

Alex also has provided tax consulting services related to merger & acquisition transactions, business transfer transactions, cross border transactions and various tax due diligence services.

Alex has strong tax technical skills and tax provision skills with extensive experience in ASC 740 and ASC 718-10 for multinational and private companies.

Shawn Kim

Managing Director, KPMG LLP

Sanghoon has over 18 years of experience in dealing with audit, tax and transfer pricing matters for multinationals operating in different industries, from manufacturing and distribution sectors to the financial industry.

Sanghoon manages tax planning, audit defense and documentation projects for significant and complex intercompany transactions, covering tangible goods, complex services, intellectual property and financing structures. He deals with tax authorities on behalf of taxpayers with respect to transfer pricing audit defense and Advance Pricing Arrangements.

Work Experience

• Dealt with tax authorities related to tax audit, tax appeal, advance pricing agreement (APA), and mutual agreement procedure (MAP)

• Assisted companies in preparing worldwide transfer pricing policies

• Assisted companies in preparing FIN 48 analyses

• Prepared transfer pricing planning study and contemporaneous transfer pricing documentations

• Prepared management service fee documentation

• Performed intellectual property valuation analyses

• Performed royalty analysis products, especially in automobile parts industry

***** Notice *****

* Please note that the webinar talk will be presented in ENGLISH language. But Q&A session will be conducted in both English and Korean.

* 이번 세미나는 Maryland 주정부 관계자 분들을 포함하여 영어권 참석자 분들이 있어, 강의는 영어로 진행될 예정입니다. 참고로 질의 응답은 영어와 한국어 모두 가능함을 안내 드립니다.